Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) is a clinical-stage biopharmaceutical company focused on neuroscience, with a pipeline targeting neurological and psychiatric disorders including schizophrenia and Parkinson's disease. The company went public in 2020 through a merger with ARYA Sciences Acquisition Corp II, a blank-check vehicle sponsored by Perceptive Advisors. By the time of its February 2024 8-K filing, Cerevel was operating under a pending all-cash acquisition agreement with AbbVie, announced in December 2023, that positioned it as one of the larger neuroscience deals of that period. The company traded on Nasdaq under CERE while the transaction awaited regulatory and shareholder clearance. Sign up for full data on SpacDesk to access Cerevel's complete filing history and deal timeline alongside thousands of other SPAC transactions.